Core binding factors are necessary for natural killer cell development, and cooperate with Notch signaling during T cell specification
Abstract
CBF{beta} is the non-DNA binding subunit of the core binding factors (CBFs). Mice with reduced CBF{beta} levels display profound, early defects in T but not B cell development. Here we show that CBF{beta} is also required at very early stages of natural killer (NK) cell development. We also demonstrate that T cell development aborts during specification, as the expression of Gata3 and Tcf7, which encode key regulators of T lineage specification, is substantially reduced, as are functional thymic progenitors. Constitutively active Notch or IL-7 signaling cannot restore T cell expansion or differentiation of CBF{beta} insufficient cells, nor can overexpression of Runx1 or CBF{beta} overcome a lack of Notch signaling. Therefore the ability of the prethymic cell to respond appropriately to Notch is dependent on CBF{beta}, and both signals converge to activate the T cell developmental program.
Additional Information
© 2008 by American Society of Hematology. Submitted October 29, 2007. Accepted March 13, 2008. Blood First Edition Paper, prepublished online April 4, 2008; DOI 10.1182/blood-2007-10-120261. An Inside Blood analysis of this article appears at the front of this issue. We gratefully acknowledge Juan Carlos Zúñiga-Pflücker for providing the OP9-DL1 cells, Michael Chen for the Runx1 virus, Richard Moriggl for the Stat5a cDNA, and Caroline Speck, Michael Chen, and Brandon Zeigler for technical assistance. This work was supported by NIH RO1CA075611 (N.A.S.) and the Damon Runyon Cancer Research Foundation DRG-102-05 (I.M.). Core services were supported in part by the Norris Cotton Cancer Center (NIH CA23108). Contribution: Y.G., S.C., and I.M. performed experiments; all authors analyzed the results; N.A.S., I.M, and Y.G. made the figures; all authors designed the research and wrote the paper. The authors declare no competing financial interests. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.Attached Files
Published - GUOblo08.pdf
Files
Name | Size | Download all |
---|---|---|
md5:1063c683e85e3cb00d7e63a25c3daf16
|
4.2 MB | Preview Download |
Additional details
- PMCID
- PMC2481540
- Eprint ID
- 10066
- DOI
- 10.1182/blood-2007-10-120261
- Resolver ID
- CaltechAUTHORS:GUOblo08
- NIH
- RO1CA075611
- Damon Runyon Cancer Research Foundation
- DRG-102-05
- NIH
- CA23108
- Created
-
2008-04-11Created from EPrint's datestamp field
- Updated
-
2021-11-08Created from EPrint's last_modified field